http://www.hcinternational.net" target="_new">http://www.hcinternational.net
CHINA BIO ENERGY HOLDING GROUP CO., LTD. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
For The Year Ended
December 31, December 31,
2008 2007
ASSETS
CURRENT ASSETS
Cash and cash equivalents $23,119,028 $1,382,371
Restricted cash 919,351 200,000
Accounts receivable 8,164,320 288,589
Other receivables and deposits 3,986,984 4,403,762
Prepaid expenses 1,884,102 41,412
Advance to suppliers 17,945,487 16,546,506
Inventories, net 22,268,903 12,082,962
Due from related party -- 593,696
Total current assets 78,288,175 35,539,298
Prepaid rents 6,408,568 --
Property and equipment, net 9,997,674 8,166,250
Total noncurrent assets 16,406,242 8,166,250
TOTAL ASSETS $94,694,417 $43,705,548
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable $ -- $179,617
Advance from customers 4,580,462 499,908
Taxes payable 735,461 125,015
Other payables 3,232,088 3,233,552
Loans payable 2,247,197 1,438,164
Total current liabilities 10,795,
'/>"/>SOURCE China Bio Energy Holdings Group Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Related biology technology :1.
aTyr Pharma to Present at ChinaBio(R) Investor Forum in Hong Kong2.
Niusule Biotech Corp. Formally Establishes a New Venture to Import and Sell Health Foods in the Peoples Republic of China3.
China-Biotics, Inc. Appoints New Chief Financial Officer4.
China Medical Technologies Senior Management Purchased Company Shares5.
China Bio-Immunity Corporation - Rabies Vaccine Recall6.
China Medicine to Participate in 2009 Natural Products Expo West Trade Show7.
China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets8.
Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent9.
Dow AgroSciences, China National Rice Research Institute Announce Collaboration on Rice Research10.
China Biologic Products High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan11.
OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China